Target intelligence / Profile preview

Microbial dysbiosis

Molecular classification
Other
01

Overview

Microbial dysbiosis refers to a disruption or imbalance of the normal microbial communities (microbiota) that inhabit body sites such as the gut, skin, or mucosa. In healthy individuals, these communities perform essential roles in digestion, immune regulation, and protection against pathogens. When this balance is disturbed—due to factors like antibiotics, poor diet, stress, infection, or environmental exposures—the resulting dysbiosis is associated with a wide range of diseases, including inflammatory, metabolic, neurodegenerative, and malignant conditions. Therapeutic strategies aim to restore a healthy microbiome through dietary changes, targeted antibiotics, probiotics, prebiotics, or fecal microbiota transplantation. However, as a community-level state rather than a discrete molecular entity, "microbial dysbiosis" is not a canonical molecular target or receptor, but rather a disease process or condition to be managed or corrected. In summary: "Microbial dysbiosis" describes an abnormal community state, not a molecular target or receptor. It is critical in health and disease, but not a druggable entity itself; instead, interventions act to shift the overall community composition or function.

Other names
dysbiosismicrobial imbalancegut dysbiosisdysbacteriosis
02

Mechanism of action

Restoration of normal microbial community structure (e.g., FMT rebalances microbiota); Removal of pathogenic or overgrown species (e.g., antibiotics); Support of beneficial microbes (e.g., probiotics/prebiotics).

03

Biological functions

Regulation of microbial community structureImmune modulationMetabolic processes (e.g., digestion, vitamin synthesis)Pathogen resistance
04

Disease associations

Inflammatory bowel disease (IBD)ObesityMetabolic disorders (diabetes, NAFLD)Neurological disorders (Parkinson’s, Alzheimer’s)Colorectal cancerCardiovascular diseasesOther chronic and infectious diseases
05

Safety considerations

Antibiotic use may worsen dysbiosis, cause opportunistic infections (e.g., Clostridioides difficile)FMT risks include pathogen transmissionOff-target effects of interventions on microbiome composition/function
06

Interacting drugs

Antibiotics

3 more in the full profile.

07

Biomarkers

Changes in relative abundance of specific taxa (e.g., Firmicutes/Bacteroidetes ratio)Reduced microbial diversityPresence of pathogenic bacteria/metabolitesFecal short-chain fatty acid (SCFA) profiles

Beyond the preview

Go deeper on Microbial dysbiosis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microbial dysbiosis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call